Longterm Effectiveness of Herpes Zoster Vaccine among Patients with Autoimmune and Inflammatory Diseases.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 28298565.
- Also identified by DOI 10.3899/jrheum.160685 and PMC identifier 5724562.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The protection duration of herpes zoster (HZ) vaccination is unclear among patients with autoimmune (AI) diseases. Using 2006-2013 Medicare data, HZ vaccinated patients with AI were matched 1:2 to unvaccinated HZ. Incidence rates (IR) and adjusted risk ratios over time were calculated using Poisson regression. Of 59,627 vaccinated patients, crude IR increased from 0.75/100 person-years during the first year post-vaccination to 1.25 during the seventh year. Vaccinated patients had a significantly lower risk of HZ compared with the unvaccinated through 5 years. HZ vaccination was significantly protective only for about 5 years among patients with AI.
Medical subject headings
- Autoimmune Diseases
- Herpes Zoster
- Herpes Zoster Vaccine
- Inflammation